Adult Congenital Heart Disease
Conditions
Keywords
adult congenital heart disease, ACHD, prognosis, long-term, follow-up
Brief summary
This is a mono-center observational ambispective study in which adult patients with congenital heart disease evaluated at our institution will be enrolled. The primary endopoint is to assess the clinical and echocardiographic predictors of adverse events during follow-up (death, arrhythmias, cardiac hospitalization). The secondary endpoints are: 1) evaluation of the incidence of the singular components of the primary endpoint; 2) evaluation of the prognostic impact of acquired lesions, including valve disease not present at birth; 3) need for surgical/percutaneous interventions during follow up. Participants will be evaluated in the context of scheduled follow-up visits in our Outpatient ACHD Clinic. No interventions/drug administration will be performed other than those required by standard clinical practice.
Interventions
None listed
Sponsors
Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Study design
Observational model
COHORT
Time perspective
CROSS_SECTIONAL
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
* Patients evaluated in our ACHD Outpatient Clinic between January 2014 and December 2026 * Age ≥ 18 years
Exclusion criteria
* Patients without congenital heart disease confirmed during the first evaluation * Impossibility to retrieve information about the first clinical evaluation in our clinic from our electonic datasets * Follow up shorter than one-year * Refused consent to participate to the study.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| cardiovascular outcomes | 5 years | composite endpoint of death and cardiac hospitalization |
| major cardiac arrhytmias | 5 years | occurence of ventricular and/or atrial arrhythmias |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| changes in echocardiographic parameters over time | 12 months | * variations in cardiac chamber size (volumes in ml, diameters in mm); * variations in left ventricular function (assessed as left ventricular ejection fraction in % using the Simpson biplane method); * variations in right ventricular systolic function (assessed as tricuspid anular plane systolic excursion in mm). |
| heart valve disease (new-onset or progression) | 12 months | progression of pre-existing heart valve disease or new-onset valve dysfunction assessed through echocardiography |
Countries
Italy
Contacts
Primary ContactFrancesca Graziani, MD, PhD
Backup ContactGiulia Iannaccone, MD
Outcome results
None listed